References
- Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian cancer statistics 2015 special topic: predictions of the future burden of cancer in Canada. Toronto (ON): Canadian Cancer Society; 2015.
- Howlader N. SEER cancer statistics review, 1975-2013. Bethesda (MD): National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
- Byers BA, Temple-Oberle CF, Hurdle V, et al. Treatment of in-transit melanoma with intra-lesional interluekin-2: a systematic review. J Surg Oncol. 2014;110:770–775.
- Temple-Oberle CF, Byers BA, Hurdle V, et al. Intra-lesional Interleukin-2 therapy for in transit melanoma. J Surg Oncol. 2014;109:327–331.
- Balch C. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199–6206.
- Gabriel E, Skitzki J. The role of regional therapies for in-transit melanoma in the era of improved systemic options. Cancers. 2015;7:1154–1177.
- Ascierto ML, Melero I, Ascierto PA. Melanoma: from incurable beast to a curable bet. The success of immunotherapy. Front Oncol. 2015;5:152.
- Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Res. 2008;18:105–111.
- Hassan S, Petrella TM, Zhang T, et al. Pathologic complete response to intralesional interleukin-2 therapy associated with improved survival in melanoma patients with in-transit disease. Ann Surg Oncol. 2015;22:1950–1958.
- Pires MC, Martins JM, Montealegre F, et al. Vitiligo after diphencyprone for alopecia areata. Dermatol Res Pract. 2010;2010:171265.
- Aghaei S. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population. BMC Dermatol. 2005;5:6.
- Harland CC, Saihan EM. Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine. Lancet. 1989;334(8660):445.
- Damian DL, Shannon KF, Saw RP, et al. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol. 2009;50:266–271.
- Kim YJ. Topical diphencyprone as an effective treatment for cutaneous metastatic melanoma. Ann Dermatol. 2012;24:373–375.
- Trefzer U, Sterry W. Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma. Dermatology. 2005;211:370–371.
- Trowbridge RM, Mitkov MV, Pittelkow MR, et al. Immunomodulation of malignant melanoma by contact sensitizing agents. Expert Rev Clin Immunol. 2014;10:63–76.
- Martiniuk F, Damian DL, Thompson JF, et al. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. J Drugs Dermatol. 2010;9:1368–1372.
- Damian DL, Saw RP, Thompson JF. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma. J Surg Oncol. 2014;109:308–313.
- Moncrieff M, Fadhil M, Garioch J. Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience. Br J Dermatol. 2016;174:1141–1142.
- National Cancer Institute. Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. May 29, 2009. version 4.03. NIH Publication. #09-7473.
- Askew RL, Xing Y, Palmer JL, et al. Evaluating minimal important differences for the FACT-melanoma quality of life questionnaire. Value Health. 2009;12:1144–1150.
- Bagge AS, Ben-Shabat I, Belgrano V, et al. Health-related quality of life for patients who have in-transit melanoma metastases treated with isolated limb perfusion. Ann Surg Oncol. 2016;23:2062–2069.
- Ross MI. Intralesional therapy with PV-10 (Rose Bengal) for in-transit melanoma. J Surg Oncol. 2014;109:314–319.
- Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg. 1974;180:635–643.